UroGen Pharma (URGN) Tops Q2 EPS by 10c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.18), $0.10 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $16.6 million versus the consensus estimate of $17.22 million.

GUIDANCE:

UroGen Pharma sees FY2022 revenue of $70-80 million, versus the consensus of $75.2 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Airbus revenue rises, delivers 142 commercial aircraft in Q1
• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance